Maven Securities’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,300
Closed -$1.39M 468
2025
Q4
$1.39M Sell
11,300
-21,000
-65% -$2.55M 0.03% 351
2025
Q3
$3.59M Buy
32,300
+8,400
+35% +$955K 0.09% 217
2025
Q2
$2.65M Buy
23,900
+15,900
+199% +$1.69M 0.06% 275
2025
Q1
$896K Buy
+8,000
New +$825K 0.03% 459
2024
Q4
Sell
-2,400
Closed -$201K 900
2024
Q3
$201K Sell
2,400
-16,600
-87% -$1.27M ﹤0.01% 848
2024
Q2
$1.3M Buy
+19,000
New +$1.27M 0.03% 471
2024
Q1
Sell
-2,600
Closed -$211K 606
2023
Q4
$211K Sell
2,600
-23,100
-90% -$1.8M ﹤0.01% 887
2023
Q3
$1.93M Buy
25,700
+1,400
+6% +$108K 0.02% 412
2023
Q2
$1.87M Buy
24,300
+600
+3% +$47.9K 0.03% 307
2023
Q1
$1.97M Sell
23,700
-1,000
-4% -$82.8K 0.04% 300
2022
Q4
$2.11M Buy
24,700
+9,600
+64% +$760K 0.05% 234
2022
Q3
$932K Sell
15,100
-7,400
-33% -$467K 0.02% 566
2022
Q2
$1.39M Buy
22,500
+21,000
+1,400% +$1.3M 0.04% 290
2022
Q1
$89K Buy
+1,500
New +$95.9K ﹤0.01% 879
2021
Q4
Sell
-5,400
Closed -$377K 955
2021
Q3
$377K Buy
+5,400
New +$379K 0.01% 758
2020
Q4
Sell
-6,900
Closed -$433K 671
2020
Q3
$433K Buy
6,900
+4,100
+146% +$284K 0.04% 414
2020
Q2
$215K Buy
+2,800
New +$215K 0.01% 488

Other funds holding GILD

Maven Securities's GILD Position: Q2 2025 in Review

Maven Securities sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 4,983 shares — an estimated $530K sold.

Maven Securities first reported a position in GILD in Q4 2016 and held it in 8 quarters. The position peaked at $1.18M in Q4 2020. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Maven Securities reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • Maven Securities sold 4,983 Gilead Sciences shares in Q2 2025, an estimated $530K.
  • Maven Securities first reported a position in Gilead Sciences in Q4 2016 and held it in 8 quarters.
  • Maven Securities's Gilead Sciences position peaked at $1.18M in Q4 2020.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Maven Securities's 13F filing for Q2 2025, filed 14 Aug 2025.